



Sociedad Médica de Laboratorio Clínico

MESA REDONDA INDICADORES DE CALIDAD EN EL LABORATORIO CLÍNICO

Expositores

Dr. Miguel Araujo

Dra. Claudia Meira

Moderadora

Dra. Ana María Guzmán

y.... ¿la acreditación de los centros de salud mejora los resultados sanitarios?

- **Mortalidad**
- **Morbilidad**
- **Días de estadía**
- **Tasas de readmisión**
- **Infecciones asociadas a la atención en salud**
- **Úlceras por presión**

Health service accreditation as a predictor of clinical and organisational performance: a blinded, random, stratified study

Qual Saf Health Care 2010;**19**:14–21. |



The Value and Impact of Health Care Accreditation: A Literature Review



Journal of **HOSPITAL MEDICINE** www.journalofhospitalmedicine.com

ORIGINAL RESEARCH

Hospital Performance Trends on National Quality Measures and the Association With Joint Commission Accreditation

El-Jardali et al. *BMC Health Services Research* 2011, **11**:45
<http://www.biomedcentral.com/1472-6963/11/45>



RESEARCH ARTICLE

Open Access

Predictors and outcomes of patient safety culture in hospitals

Fadi El-Jardali^{1*}, Hani Dimassi², Diana Jamal¹, Maha Jaafar¹, Nour Hemadeh³

Managing to improve quality: The relationship between accreditation standards, safety practices, and patient outcomes

Health Care Manage Rev, 2009, **34**(3), 262-272
Copyright © 2009 Wolters Kluwer Health | Lippincott Williams & Wilkins

Managing to improve quality: The relationship between accreditation standards, safety practices, and patient outcomes

Health Care Manage Rev, 2009, 34(3), 262-272

Deirdre K. Thornlow

Elizabeth Merwin

- 1.430.981 egresos (115 hospitales USA)
- Fuerte asociación entre acreditación
 - IAAS
 - úlceras de decúbito
- Pobre asociación
 - falla respiratoria post-operatoria
 - fracaso de re-animación CP

ORIGINAL RESEARCH

Hospital Performance Trends on National Quality Measures and the Association With Joint Commission Accreditation

INFARTO AGUDO AL MIOCARDIO	INSUFICIENCIA CARDÍACA	NEUMONIA
Aspirina admisión	Instrucciones al alta	Evaluación oxigenación
Aspirina alta	Evaluación función VI	Vacuna neumococo
Inhibidor ECA en disfunción VI	Inhibidor ECA en disfunción VI	Inicio precoz terapia antibiótica
Beta-bloqueadores alta	Consejería suspender tabaco	Selección inicial antibiótico
Consejería suspender tabaco		Consejería suspender tabaco
Intervención coronaria percutánea dentro 90min		
Terapia trombolítica antes de 30 min		

ORIGINAL RESEARCH

Hospital Performance Trends on National Quality Measures and the Association With Joint Commission Accreditation

Quality Measure, Mean (SD)*	2004			2008		
	Non-Accredited (n = 786)	Accredited (n = 3105)	P Value†	Non-Accredited (n = 950)	Accredited (n = 2,941)	P Value†
AMI						
Aspirin at admission	87.1 (20.0)	92.6 (9.4)	<0.001	88.6 (22.1)	96.0 (8.6)	<0.001
Aspirin at discharge	81.2 (26.1)	88.5 (14.9)	<0.001	87.8 (22.7)	94.8 (10.1)	<0.001
ACE inhibitor for LV dysfunction	72.1 (33.4)	76.7 (22.9)	0.010	83.2 (30.5)	92.1 (14.8)	<0.001
Beta blocker at discharge	78.2 (27.9)	87.0 (16.2)	<0.001	87.4 (23.4)	95.5 (9.9)	<0.001
Smoking cessation advice	59.6 (40.8)	74.5 (29.9)	<0.001	87.2 (29.5)	97.2 (11.3)	<0.001
PQ received within 90 min	60.3 (26.2)	60.6 (23.8)	0.946	70.1 (24.8)	77.7 (19.2)	0.006
Thrombolytic agent within 30 min	27.9 (35.5)	32.1 (32.8)	0.152	31.4 (40.7)	43.7 (40.2)	0.008
Composite AMI score	80.6 (20.3)	87.7 (10.4)	<0.001	85.8 (20.0)	94.6 (8.1)	<0.001
Heart failure						
Discharge instructions	36.8 (32.3)	49.7 (28.2)	<0.001	67.4 (29.6)	82.3 (16.4)	<0.001
Assessment of LV function	63.3 (27.6)	83.6 (14.9)	<0.001	79.6 (24.4)	95.6 (8.1)	<0.001
ACE inhibitor for LV dysfunction	70.8 (27.6)	75.7 (16.3)	<0.001	82.5 (22.7)	91.5 (9.7)	<0.001
Smoking cessation advice	57.1 (36.4)	68.6 (26.2)	<0.001	81.5 (29.9)	96.1 (10.7)	<0.001
Composite heart failure score	56.3 (24.1)	71.2 (15.6)	<0.001	75.4 (22.3)	90.4 (9.4)	<0.001
Pneumonia						
Oxygenation assessment	97.4 (7.3)	98.4 (4.0)	<0.001	99.0 (3.2)	99.7 (1.2)	<0.001
Pneumococcal vaccination	45.5 (29.0)	48.7 (26.2)	0.007	79.9 (21.3)	87.9 (12.9)	<0.001
Timing of initial antibiotic therapy	80.6 (13.1)	70.9 (14.0)	<0.001	93.4 (9.2)	93.6 (6.1)	0.525
Smoking cessation advice	56.6 (33.1)	65.7 (24.8)	<0.001	81.6 (25.1)	94.4 (11.4)	<0.001
Initial antibiotic selection	73.6 (19.6)	74.1 (13.4)	0.508	86.1 (13.8)	88.6 (8.7)	<0.001
Composite pneumonia score	77.2 (10.2)	76.6 (8.2)	0.119	90.0 (9.6)	93.6 (4.9)	<0.001
Overall composite	73.7 (10.6)	78.0 (8.7)	<0.001	86.8 (11.1)	93.3 (5.0)	<0.001

TABLE 3. Performance Change and Difference in Performance Change From 2004 to 2008 by Joint Commission Accreditation Status

Characteristic	Change in Performance*		Absolute Difference, Always vs Never (95% CI) [†]	Relative Difference, % Always vs Never	P Value [†]
	Never Accredited (n = 762)	Always Accredited (n = 2,917)			
AMI					
Aspirin at admission	-1.1	2.0	3.2 (1.2-5.2)	160	0.001
Aspirin at discharge	4.7	8.0	3.2 (1.4-5.1)	40	0.008
ACE inhibitor for LV dysfunction	8.5	15.9	7.4 (3.7-11.5)	47	<0.001
Beta blocker at discharge	4.4	8.4	4.0 (2.0-6.0)	48	<0.001
Smoking cessation advice	18.6	22.4	3.7 (1.1-6.9)	17	0.012
PCI received within 90 min	6.3	13.0	6.7 (0.3-14.2)	52	0.070
Thrombolytic agent within 30 min	-0.6	5.4	6.1 (-9.5-20.4)	113	0.421
Composite AMI score	2.0	5.8	3.9 (2.2-5.5)	67	<0.001
Heart failure					
Discharge instructions	24.2	35.6	11.4 (8.7-14.0)	32	<0.001
Assessment of LV function	4.6	12.8	8.3 (6.6-10.0)	65	<0.001
ACE inhibitor for LV dysfunction	10.1	15.2	5.1 (3.5-6.8)	34	<0.001
Smoking cessation advice	20.5	26.4	6.0 (3.3-8.7)	23	<0.001
Composite heart failure score	10.8	20.9	10.1 (8.3-12.0)	48	<0.001
Pneumonia					
Oxygenation assessment	0.9	1.4	0.6 (0.3-0.9)	43	<0.001
Pneumococcal vaccination	33.4	40.9	7.5 (5.6-9.4)	18	<0.001
Timing of initial antibiotic therapy	19.2	21.1	1.9 (1.1-2.7)	9	<0.001
Smoking cessation advice	21.8	27.9	6.0 (3.8-8.3)	22	<0.001
Initial antibiotic selection	13.6	14.3	0.7 (-0.5-1.9)	5	0.293
Composite pneumonia score	13.7	17.5	3.7 (2.8-4.6)	21	<0.001
Overall composite	12.0	16.1	4.2 (3.2-5.1)	26	<0.001

